Remicade (infliximab) denied for missing prior authorization by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare Is Denying Your Remicade Prescription

A "prior authorization required" denial on Remicade (infliximab) from UnitedHealthcare is almost never about Remicade being non-covered — it's about UHC's commercial biosimilar preference architecture. Under the Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – UnitedHealthcare Commercial Medical Benefit Drug Policy (effective 02.01.2026), Avsola and Inflectra are the preferred infliximab products, and Remicade (HCPCS J1745) is gated behind a biosimilar step-therapy wall enforced through OptumRx's medical-benefit PA channel. The denial letter you received is the system functioning as designed — UHC will not pay for Remicade until you affirmatively document one of three carve-outs in the policy.

The three doors into Remicade coverage. UHC's policy gives you precisely three avenues: (1) at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, (2) a physician attestation that clinical response would be expected to be superior with Remicade than with the preferred biosimilars, or (3) documented intolerance, contraindication, or adverse event to Avsola/Inflectra plus an attestation that the same event would not be expected with Remicade. Most denials happen because the prescriber's PA submission asserted medical necessity in generic terms without naming the preferred agents and the attestation language verbatim. UHC's Optum reviewers are scanning for the specific words.

Indication-specific step therapy still applies on top. Even if you clear the biosimilar gate, the indication criteria must also be met — for ankylosing spondylitis, two NSAIDs at maximally indicated doses for ≥4 weeks each (or a prior FDA-approved targeted immunomodulator); for plaque psoriasis, ≥3% BSA involvement or palmoplantar/facial/genital disease plus failed topical therapy. Combination therapy with another targeted immunomodulator (adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for the same indication is an automatic denial, as is a missing latent TB test per the prescribing information.

Federal leverage points. Under 29 USC §1185d, ERISA plans must offer a step-therapy override pathway where the required step therapy has been tried, would be ineffective, would cause harm, or where the patient is stable on the requested drug. Under 29 CFR §2560.503-1, UHC must produce the actual policy criteria and the clinical rationale on appeal — boilerplate "does not meet criteria" denials are facially deficient. If UHC's reviewer applies criteria more rigidly than the written policy, Pinto v. Aetna (10th Cir. 2014) supports the argument that the burden shifts to the plan to justify a restrictive reading.

Tactical tip: Submit the appeal through the OptumRx medical benefit PA portal (not the pharmacy benefit side — Remicade is buy-and-bill under J1745), and quote the policy's attestation language verbatim in the prescriber letter: "In my clinical opinion, the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola because [patient-specific reason]." Attach infusion records, prior biosimilar trial documentation with specific dates and response measures (CDAI, HBI, PASI, BASDAI as applicable), and the latent TB test result. If denied again, escalate to external IRO review under your state's insurance code — UHC commercial denials overturned at IRO are binding.